News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
MarketBeat on MSN56m
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Energy stocks posted declines after the [U.S. attacked Iranian nuclear facilities](http ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback